We are live on ! Find out more
KFO

Kopp Family Office Portfolio holdings

AUM $163M
1-Year Est. Return 22.57%
This Fund
S&P 500
This Quarter Est. Return
+23.74%
1 Year Est. Return
+22.57%
3 Year Est. Return
+33.98%
5 Year Est. Return
+1.93%
10 Year Est. Return
–
AUM
$185M
AUM Growth
+$39.4M
Cap. Flow
+$14.3M
Cap. Flow %
7.72%
Top 10 Hldgs %
100%
Holding
6
New
1
Increased
3
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$13.5M
2
VCEL icon
Vericel Corp
VCEL
+$4.52M
3
FIVN icon
FIVE9
FIVN
+$2.43M
4
NEO icon
NeoGenomics
NEO
+$83.1K

Top Sells

Rank Stock Value
1
SRGA
Surgalign Holdings, Inc. Common Stock
SRGA
+$6.17M
2
XENT
Intersect ENT, Inc
XENT
+$116K

Sector Composition

Rank Sector Weight
1 Healthcare 95.61%
2 Technology 3.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NEO icon
1
NeoGenomics
NEO
$1.96B
$144M 78.03%
4,661,835
+3,000
+0.1% +$83.1K
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$17.6M 9.5%
+316,325
New +$13.5M
VCEL icon
3
Vericel Corp
VCEL
$2.35B
$15M 8.08%
1,082,155
+333,900
+45% +$4.52M
FIVN icon
4
FIVE9
FIVN
$2.11B
$7.08M 3.83%
63,995
+25,000
+64% +$2.43M
XENT
5
DELISTED
Intersect ENT, Inc
XENT
$1.05M 0.57%
77,630
-10,000
-11% -$116K
SRGA
6
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
– –
-120,257
Closed -$6.17M

Similar funds

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
GP
Gridiron Partners Wexford, Pennsylvania $164M AUM 3.31% 1-Year Est. Return
PWAM
Papamarkou Wellner Asset Management New York $164M AUM 25.23% 1-Year Est. Return

Kopp Family Office's Q2 2020 Portfolio in Review

As of Q2 2020, Kopp Family Office held 6 positions worth $185M, up 27% from $146M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Kopp Family Office deployed $14.3M of net new capital in Q2 2020, opening 1 new position and adding to 3 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 316,325 shares worth $17.6M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Intersect ENT, Inc, an estimated $116K trimmed.

  • Kopp Family Office's largest Q2 2020 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 316,325 shares worth $17.6M.
  • Kopp Family Office added most to Vericel Corp in Q2 2020, an estimated $4.52M increase.
  • Kopp Family Office's biggest Q2 2020 reduction was Intersect ENT, Inc, cutting an estimated $116K.
  • Kopp Family Office fully exited Surgalign Holdings, Inc. Common Stock in Q2 2020, selling an estimated $6.17M.
  • Kopp Family Office's ten largest holdings make up 100% of its $185M portfolio in Q2 2020.
  • Kopp Family Office opened 1 new position and closed 1 in Q2 2020.
  • Kopp Family Office's portfolio value rose 27% quarter-over-quarter to $185M.

Based on Kopp Family Office's 13F filing for Q2 2020, filed 14 Aug 2020.